Straumann Holding Valuation
Is STMN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of STMN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: STMN (CHF125.45) is trading below our estimate of fair value (CHF140.5)
Significantly Below Fair Value: STMN is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STMN?
Other financial metrics that can be useful for relative valuation.
What is STMN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF 20.00b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.9x |
Enterprise Value/EBITDA | 28.9x |
PEG Ratio | 3.2x |
Price to Earnings Ratio vs Peers
How does STMN's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 34.8x | ||
SOON Sonova Holding | 29.3x | 8.5% | CHF 17.6b |
MOVE Medacta Group | 58.2x | 20.0% | CHF 2.6b |
METN Metall Zug | 8x | -29.5% | CHF 549.0m |
ALC Alcon | 43.4x | 10.9% | CHF 40.7b |
STMN Straumann Holding | 69.5x | 21.8% | CHF 20.0b |
Price-To-Earnings vs Peers: STMN is expensive based on its Price-To-Earnings Ratio (69.5x) compared to the peer average (34.8x).
Price to Earnings Ratio vs Industry
How does STMN's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: STMN is expensive based on its Price-To-Earnings Ratio (69.5x) compared to the European Medical Equipment industry average (31.4x).
Price to Earnings Ratio vs Fair Ratio
What is STMN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 69.5x |
Fair PE Ratio | 51.4x |
Price-To-Earnings vs Fair Ratio: STMN is expensive based on its Price-To-Earnings Ratio (69.5x) compared to the estimated Fair Price-To-Earnings Ratio (51.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 125.45 | CHF 134.83 +7.5% | 16.9% | CHF 175.00 | CHF 90.00 | n/a | 18 |
Aug ’25 | CHF 113.45 | CHF 134.33 +18.4% | 18.1% | CHF 175.00 | CHF 90.00 | n/a | 18 |
Jul ’25 | CHF 112.70 | CHF 134.39 +19.2% | 18.4% | CHF 175.00 | CHF 90.00 | n/a | 18 |
Jun ’25 | CHF 117.00 | CHF 135.94 +16.2% | 18.2% | CHF 175.00 | CHF 90.00 | n/a | 18 |
May ’25 | CHF 123.00 | CHF 138.67 +12.7% | 18.4% | CHF 175.00 | CHF 90.00 | n/a | 18 |
Apr ’25 | CHF 144.00 | CHF 142.32 -1.2% | 18.4% | CHF 175.00 | CHF 90.00 | n/a | 19 |
Mar ’25 | CHF 142.75 | CHF 134.22 -6.0% | 17.7% | CHF 168.00 | CHF 90.00 | n/a | 18 |
Feb ’25 | CHF 137.45 | CHF 128.22 -6.7% | 16.1% | CHF 153.00 | CHF 90.00 | n/a | 18 |
Jan ’25 | CHF 135.60 | CHF 125.41 -7.5% | 15.2% | CHF 150.00 | CHF 90.00 | n/a | 17 |
Dec ’24 | CHF 119.85 | CHF 124.47 +3.9% | 14.8% | CHF 150.00 | CHF 90.00 | n/a | 17 |
Nov ’24 | CHF 105.60 | CHF 131.99 +25.0% | 16.8% | CHF 167.00 | CHF 90.00 | n/a | 17 |
Oct ’24 | CHF 117.20 | CHF 135.38 +15.5% | 18.0% | CHF 167.00 | CHF 90.00 | n/a | 16 |
Sep ’24 | CHF 133.85 | CHF 136.82 +2.2% | 17.7% | CHF 167.00 | CHF 90.00 | n/a | 17 |
Aug ’24 | CHF 144.15 | CHF 134.47 -6.7% | 20.4% | CHF 165.00 | CHF 82.00 | CHF 113.45 | 17 |
Jul ’24 | CHF 145.15 | CHF 133.76 -7.8% | 21.1% | CHF 165.00 | CHF 82.00 | CHF 112.70 | 17 |
Jun ’24 | CHF 135.10 | CHF 131.88 -2.4% | 22.3% | CHF 165.00 | CHF 82.00 | CHF 117.00 | 16 |
May ’24 | CHF 133.65 | CHF 124.87 -6.6% | 21.4% | CHF 160.00 | CHF 82.00 | CHF 123.00 | 15 |
Apr ’24 | CHF 136.35 | CHF 124.53 -8.7% | 21.8% | CHF 160.00 | CHF 82.00 | CHF 144.00 | 15 |
Mar ’24 | CHF 123.95 | CHF 120.43 -2.8% | 21.2% | CHF 158.00 | CHF 80.00 | CHF 142.75 | 14 |
Feb ’24 | CHF 120.95 | CHF 116.21 -3.9% | 20.4% | CHF 150.00 | CHF 80.00 | CHF 137.45 | 14 |
Jan ’24 | CHF 105.60 | CHF 119.00 +12.7% | 18.7% | CHF 150.00 | CHF 88.00 | CHF 135.60 | 13 |
Dec ’23 | CHF 108.65 | CHF 122.08 +12.4% | 17.9% | CHF 153.00 | CHF 90.00 | CHF 119.85 | 12 |
Nov ’23 | CHF 95.18 | CHF 129.29 +35.8% | 23.9% | CHF 205.00 | CHF 90.00 | CHF 105.60 | 13 |
Oct ’23 | CHF 91.84 | CHF 137.25 +49.4% | 24.6% | CHF 205.00 | CHF 90.00 | CHF 117.20 | 11 |
Sep ’23 | CHF 104.55 | CHF 147.50 +41.1% | 18.2% | CHF 205.00 | CHF 90.00 | CHF 133.85 | 12 |
Aug ’23 | CHF 127.80 | CHF 154.67 +21.0% | 20.8% | CHF 205.00 | CHF 90.00 | CHF 144.15 | 12 |
Analyst Forecast: Target price is less than 20% higher than the current share price.